Bank of America 2026 Global Agriculture and Materials Conference

Stephan Tanda

President and CEO

Mary Skafidas

SVP, Investor Relations & Communications

Bank of America 2026 Global Agriculture and Materials Conference

February 25, 2026

1

Aptar is a Global Leader in Drug and Consumer Product Dosing, Dispensing and Protection Technologies

2025 % of Total Reported Sales

Beverage 5%

Food

We combine product design, engineering and science to create core differentiating technologies.

Proprietary drug delivery systems provide a competitive edge,

Home Care 3%

Personal

10%

Closures 19%

Pharma

2

Proprietary Drug Delivery Systems3

33%

driven by a strong innovation pipeline and over 7,000 active and pending patents in our portfolio.

Each segment has attractive growth potential. Consistently recognized as a sustainability leader.

Robust balance sheet providing ample opportunity to deploy

Care 16%

Fragrance, Facial

Beauty 35%

$3.8B

46%

Injectables 8%

firepower - 1-3x leverage corridor long-term target.

Over the last five years, we have returned about $1.2B to shareholders through dividends and share repurchases.

Skincare and Color Cosmetics

20%

Active Material Science Solutions 5%

1: Adjusted EBITDA - See Appendix for definition.

2: 2025 Annual Revenue.

3: Proprietary Drug Delivery Devices includes Prescription, Consumer Healthcare and Digital health Markets.

3

Technologies and Industrial Capabilities Deployed Across End Markets

In Place

Developing

Proprietary Technology Platforms1

Industrial Capabilities

Dispensing Fine Mist Pumps Dispensing Closures Dispensing Lotion Pumps Active Materials

Elastomeric Components Airless Systems

Aerosol Valves & Bag-On-Valves Services

Digital + Connected Devices Precision Injection Molding High Speed Assembly, AI QC2 Metal Stamping & Anodizing Decoration

Pharma Beauty Personal Care Home Care Beverage Food

Sustainable Solutions

Industry Leading Innovation, Unmatched Reliability

Closures

16%

22%

7,300+

Patents (granted or pending)

62%

Consistent Patent Investments1

Beauty

Pharma

Our advanced dispensing and dosing solutions are intended to maximize user satisfaction, delivering superior value to both customers and end users.

R&D spend as a percentage of sales for Aptar is ~3%3 with a larger portion of the R&D spend going to Pharma

• Proprietary Intellectual Property

  Aptar designs and owns its IP

• Pharmaceutical Excellence

  Aptar meets ISO 5, 6, 7, 8, and 9 cleanroom standards, with clean rooms in every facility to help ensure product integrity and safety

• Regulatory Expertise and High Reliability

  Aptar supports emergency medicines with demonstrated reliability of 99.999%2. Regulatory know-how makes us a key partner, accelerating success from strategy to commercialization

• Advanced Dispensing Solutions

  Aptar's proprietary technologies deliver high-performance dispensing, enhancing patient and consumer experiences

• Innovation & Rapid Development

  Integrated labs and prototyping accelerate efficient solution design

• Human Factors Expertise

  We embed human factors into design to help ensure safety, usability, and a superior user experience

  1: Granted and pending as of April 2025 based on company research and publicly available information

  2. As demonstrated in NDA filings using our dispensing systems for emergency situations 3: For fiscal year 2025.

  5

  Well-Positioned for Long-Term Revenue Growth

  Beauty

  $38B

  Pharma

  $165B

  Closures

  $7B

Beauty

~4%

Pharma

~7%

Total Addressable Market Across Aptar's Growing End Markets1

Long-Term Market Projected Growth Rates

Prioritizing Capital Deployment for Highest Returns

We remain focused on selective and disciplined capital allocation

Repurchases - $0.9B

Dividends - $0.9B

17%

17%

66%

CapEx & Acquisitions - $3.5B

Pharma ~50%

• Profitable organic growth powered by disciplined capital allocation

• Continued emphasis on strategic acquisitions and high-value partnerships

• Consistent return of shareholder value through dividends and share repurchases

• ~Two-thirds of capital reinvested into core business operations and growth initiatives

  $1.2B

  Returned to shareholders through dividends and share repurchases

  over the last five years

• ~One-third of capital returned to shareholders

2017 - 2025

Recent Recognitions

Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers

CDP

Climate A List

Newsweek

In the Top 100

America's Most Responsible

Forbes

One of the

World's Top Companies For

TIME

One of the

World's Most Sustainable

CDP

Recognized as a

Supplier Engagement

EcoVadis

Sustainability Rating

Platinum

Top 1%

Barron's*

In the Top 100

Most Sustainable Companies

ISS ESG

Achieved

Prime Status

USA Today

One of

America's Climate Leaders

Le Point

One of the Most

Responsible Companies

*Used with permission. ©2025 Dow Jones & Company, Inc.

8

Aptar Pharma

Aptar Pharma - At a Glance

FY 2025 % of Pharma Segment Sales

Active Material Science Solutions

10%

Injectable Solutions

& Components

Proprietary Drug

Delivery Systems1

19%

$1.7B

in Revenue

71%

We are a proprietary leader in precision drug dosing and dispensing active in highly regulated markets

• IP Breadth

• Diversified Portfolio

• Conversion: Originator → Generic Transition → OTC

• Regulatory expertise makes us a trusted partner

• Our services help enable early engagement

• Our digital health offerings set us apart from other suppliers

• A strong balance sheet supports pharma investment and long-term strength

FY 2025

Core Sales Growth %2 3%

Adjusted EBITDA Margin %2 35.0%

% of Total Revenue 46%

% of Total Adjusted EBITDA2 69%

1: Proprietary Drug Delivery Devices includes Prescription, Consumer Healthcare and Digital health Markets.

Strong Market Position Fortified by Differentiated Position Aptar Pharma's Strengths

Increasing Regulatory Complexity

Proven track record in supporting approval of combination products (molecule + delivery system) in US and EU. Our experts work collaboratively with regulatory agencies to address new product specific guidance.

Significant Engineering & Scientific Know-How

Strong IP Portfolio, bolstered by decades of expertise. Our scientific affairs teams are building an understanding of pathway modeling.

Quality & Reliability

Proven reliability. Multiple market references with a proven regulatory track record.

Long-Standing Customer and Partner Relationships

30+ years of experience. Established lines eliminates capacity reservation.

Capital Intensity

Global footprint -- Significant investment in manufacturing capacity has improved our ability to meet customer needs and market demands.

Total Drug Sales by Delivery Route

Dermal / Transdermal

Well positioned with proprietary products Technology platform shared with Beauty segment

Respiratory

2%

Eye Care

Well positioned with proprietary products

Other Routes

Well positioned with proprietary products

5% 4%

1%

43%

$1.7T

Total Drug Sales Market1

45%

Oral

Strong growth potential

Focused on specialized high-value market for drugs with sensitive formulations

Injectables

Growing position with expanded capacity in

High-Value Product offerings

Aptar Pharma: Global Reach, Trusted Partner, Broad Offerings

$2,000

Reported Net Sales

(in Millions $)

$700

Adjusted EBITDA

(in Millions $)

$1,800

$1,600

$1,400

$600

$500

$1,200

$1,000

$800

$400

$300

$600

$400

$200

$-

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

$200

$100

$-

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

FY 2025

Net Sales

Reported Net Sales Growth % Adjusted EBITDA1

Adjusted EBITDA Margin %1

$1.7B

6%

$608M 35.0%

1: See Appendix for definitions.

13

Prescription Drug Therapeutic Areas

For Respiratory, Injectable, Ophthalmic, and Dermal Drug Delivery Routes

Top Therapeutic Areas by Average Weighted Value of Opportunities in Pipeline

(As of September 30, 2025)

1. Respiratory

2. Biologics (Inj.)

3. Systemic Nasal Drug Delivery

   o Central nervous system (CNS), Pain management, Emergency medicine

4. Small Molecule (Inj.)

5. Ophthalmology

6. Allergic Rhinitis

7. Vaccines (Inj. and Nasal)

8. Dermatology

Key Takeaways

• Diverse therapeutic areas support a well-diversified portfolio

• Injectables have taken an increasingly prominent role in the pipeline

• As systemic nasal drug delivery expanded, nasally delivered CNS therapies represented the majority of opportunities

• Historically, the pipeline contributes about 10% of annual revenue, while 90% is driven by repeat business*

  Our core business continues to deliver-systemic nasal delivery is accelerating, and Injectables now accounts for a greater portion of the pipeline

• Pharma's primary growth driver has been volume growth and favorable mix shift within repeat business

  Deep-dive of Proprietary Drug Delivery Systems Pipeline
  
  

  Metabolism

  Obesity Diabetes

  Musculoskeletal

  Muscular Dystrophy Creatine Deficiency ALS

  Vaccine & Antiviral

  COVID-19 RSV

  Influenza Universal Flu mAbs / mRNA

  Cardiovascular

  Molecules

  Neurological Disorders

  Autism Spectrum Sleep Disorders Prader-Willi

  Neurodegeneration

  Alzheimer's Dementia Parkinson's Huntington Multiple Sclerosis

  Aging

  Eye Diseases

  Dry Eye Glaucoma

  Mental Health

  Stroke / Heart Failure Cardiac Arrhythmia

  Edema and Tachycardia (Just Approved)

  ADHD

  PTSD / Anxiety Schizophrenia

  Depression Addiction

  Bipolar Disorders

  Oncology

  Glioblastoma Breast Cancer Brain Cancer Meningioma

  Traumatic Injury

  Traumatic Brain Injury Newborn Brain Damage Spinal Cord Injury

  Lifecycle of a Nasally Delivered Molecule Using Aptar's Proprietary Drug Delivery System

  Development

  1988

  Originator

  1994

  Generics

  2006

  Brand Extension 2007

  Originator Goes

  OTC Status

  2014

  Generics Go

  OTC

  2017

  Drug X first approved for prescription in 1994 with Aptar's nasal delivery system (1st generation) in its Drug Master File (DMF)

• Using Aptar's Delivery technology remains the delivery system (with improvements, IP, etc.) throughout the lifecycle of the drug

• More than 3 billion Aptar delivery systems have been sold for this molecule

• Aptar has received revenue for its respective delivery systems for this molecule for 30 years and counting

Revenue from Drug X

30x

in revenue

One molecule can create sustained revenue

Pipeline launches add to steady stream of revenue from growing repeat business1

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

Originator Generic OTC

Added Early-Stage and Late-Stage Capabilities to Bolster Core Business

Discovery

Clinical Trial Development

Market Launch and LCM

Discovery and

Pre-Clinical

From Phase I to Phase III

Commercial

Phase IV and LCM

Services support, accelerate and derisk our customers' product development and enhance patients' experiences

From NDAs to ANDAs and 505b2 filings, our regulatory expertise and

Historical positioning

credibility help derisk pharma company's submissions by leveraging 30+

years of experience supporting our customers and responding to regulators

API

Device C

Formulation

Patient

Insight

Analytical

testing

Human

Factors

Clinical

supplies

Regulatory

support

Clinical

Manufacturing

Commercial

Manufacturing C Release

Patient

onboarding

Device supply-patient

monitoring solutions

Design

fo

rmulation d

Device G

ev.

Clinical trials

Regulatory fillings

Manufacturing

Market launch G post-launch

Adding Value Throughout the Drug Development Process

Pharma Full Year 2025 Results

$2,000

$1,800

$1,600

$1,400

$1,200

$1,000

$800

$600

$400

$200

$-

FY 2025 Sales

$1,737

$1,643

Reported

6%

Core

3%

Acquisitions

0%

Currency Effects

3%

(in millions $)

FY 2024 FY 2025

40%

30%

20%

10%

0%

Adjusted EBITDA Margin %1

34.6%

35.0%

FY 2024 FY 2025

Full Year 2025

• Reported sales grew 6% to $1.74B, core sales up 3% as strong volume and higher royalties offset lower tooling sales and pricing adjustments.

• Prescription drug delivery core sales up 5%, driven by higher demand for emergency medicine and CNS solutions, plus increased royalty revenue, even with the destocking of Naloxone delivery systems in the fourth quarter.

• Consumer healthcare core sales down 8%, however the segment returned to growth after a period of inventory management in the cold and cough space. Growth in eye care solutions remained strong.

• Injectables core sales up 11% on strong GLP-1 component demand; active material science core sales up 3% as higher

film/diabetes solution demand outweighed last year's large tooling sale.

Aptar Beauty

Aptar Beauty: At a Glance

FY 2025 % of Beauty Segment Sales Sales By Region

(FY 2025 by Ship To Destination)

18%

61%

9%

12%

Home Care

5%

Fragrance, Facial

Skincare and Color Cosmetics

37%

$1.3B

in revenue

58%

Personal

Care

A significant amount of Europe sales end up in Asia and U.S.

1